# Farmers & Merchants Bancorp Inc: financial statements, quarterly

FMAO · Nasdaq · CIK 792966 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fmao.md) · [Financials](/companies/fmao/financials.md) · [Filings](/companies/fmao/filings.md) · [Insiders](/companies/fmao/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fmao/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative | $m | [1.3](/filings/0000950170-24-122145.md) | [1.5 d](/filings/0001193125-26-081475.md) | [1.3](/filings/0000950170-25-063499.md) | [1.5](/filings/0000950170-25-101771.md) | [1.1](/filings/0001193125-25-260124.md) | [1.5 d](/filings/0001193125-26-081475.md) | [1.5](/filings/0001193125-26-190726.md) | [1.9](/filings/0001193125-26-323955.md) | [1.3](/filings/0001193125-25-260124.md) | [1.2 d](/filings/0001193125-26-081475.md) | [1.7](/filings/0001193125-26-190726.md) | [1.6](/filings/0001193125-26-323955.md) |
| Interest expense | $m | [16.7](/filings/0000950170-24-021373.md) | [18.3](/filings/0000950170-24-021373.md) | [18.5](/filings/0000950170-24-055094.md) | [19.8](/filings/0000950170-24-092627.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.1](/filings/0000950170-25-027602.md) | [1.3](/filings/0000950170-25-027602.md) | [1.4](/filings/0001193125-26-081475.md) | [1.5](/filings/0001193125-26-081475.md) | [1.6](/filings/0001193125-26-081475.md) | [2.1](/filings/0001193125-26-081475.md) | [1.8](/filings/0001193125-26-190726.md) | [2.0](/filings/0001193125-26-323955.md) | [2.4](/filings/0001193125-26-081475.md) | [3.0](/filings/0001193125-26-081475.md) | [2.8](/filings/0001193125-26-190726.md) | [3.0](/filings/0001193125-26-323955.md) |
| Net income | $m | [4.8](/filings/0000950170-25-027602.md) | [5.5](/filings/0000950170-25-027602.md) | [5.4](/filings/0001193125-26-081475.md) | [5.7](/filings/0001193125-26-081475.md) | [6.5](/filings/0001193125-26-081475.md) | [8.4](/filings/0001193125-26-081475.md) | [7.0](/filings/0001193125-26-323955.md) | [7.7](/filings/0001193125-26-323955.md) | [8.9](/filings/0001193125-26-081475.md) | [9.8](/filings/0001193125-26-081475.md) | [9.6](/filings/0001193125-26-323955.md) | [11.8](/filings/0001193125-26-323955.md) |
| Diluted EPS | $ per share | [0.35](/filings/0000950170-25-027602.md) | [0.41](/filings/0000950170-25-027602.md) | [0.39](/filings/0001193125-26-081475.md) | [0.42](/filings/0001193125-26-081475.md) | [0.48](/filings/0001193125-26-081475.md) | [0.61](/filings/0001193125-26-081475.md) | [0.51](/filings/0001193125-26-190726.md) | [0.56](/filings/0001193125-26-323955.md) | [0.64](/filings/0001193125-26-081475.md) | [0.71](/filings/0001193125-26-081475.md) | [0.70](/filings/0001193125-26-190726.md) | [0.86](/filings/0001193125-26-323955.md) |
| Basic EPS | $ per share | [0.35](/filings/0000950170-25-027602.md) | [0.41](/filings/0000950170-25-027602.md) | [0.39](/filings/0001193125-26-081475.md) | [0.42](/filings/0001193125-26-081475.md) | [0.48](/filings/0001193125-26-081475.md) | [0.61](/filings/0001193125-26-081475.md) | [0.51](/filings/0001193125-26-190726.md) | [0.56](/filings/0001193125-26-323955.md) | [0.64](/filings/0001193125-26-081475.md) | [0.71](/filings/0001193125-26-081475.md) | [0.70](/filings/0001193125-26-190726.md) | [0.86](/filings/0001193125-26-323955.md) |

- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [3,235](/filings/0000950170-23-057318.md) | [3,283](/filings/0000950170-25-027602.md) | [3,288](/filings/0000950170-24-055094.md) | [3,323](/filings/0000950170-24-092627.md) | [3,389](/filings/0000950170-24-122145.md) | [3,365](/filings/0001193125-26-081475.md) | [3,389](/filings/0000950170-25-063499.md) | [3,346](/filings/0000950170-25-101771.md) | [3,391](/filings/0001193125-25-260124.md) | [3,434](/filings/0001193125-26-323955.md) | [3,486](/filings/0001193125-26-190726.md) | [3,502](/filings/0001193125-26-323955.md) |
| Total liabilities | $m | [2,931](/filings/0000950170-23-057318.md) | [2,967](/filings/0000950170-25-027602.md) | [2,970](/filings/0000950170-24-055094.md) | [3,000](/filings/0000950170-24-092627.md) | [3,054](/filings/0000950170-24-122145.md) | [3,030](/filings/0001193125-26-081475.md) | [3,044](/filings/0000950170-25-063499.md) | [2,995](/filings/0000950170-25-101771.md) | [3,029](/filings/0001193125-25-260124.md) | [3,064](/filings/0001193125-26-323955.md) | [3,110](/filings/0001193125-26-190726.md) | [3,117](/filings/0001193125-26-323955.md) |
| Shareholders' equity | $m | [303](/filings/0000950170-24-122145.md) | [317](/filings/0001193125-26-081475.md) | [318](/filings/0001193125-25-260124.md) | [323](/filings/0001193125-25-260124.md) | [335](/filings/0001193125-25-260124.md) | [335](/filings/0001193125-26-323955.md) | [345](/filings/0001193125-26-323955.md) | [351](/filings/0001193125-26-323955.md) | [362](/filings/0001193125-25-260124.md) | [371](/filings/0001193125-26-323955.md) | [376](/filings/0001193125-26-323955.md) | [385](/filings/0001193125-26-323955.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4.8 d](/filings/0000950170-24-122145.md) | [10.6 d](/filings/0001193125-26-081475.md) | [1.5](/filings/0000950170-25-063499.md) | [9.7 d](/filings/0000950170-25-101771.md) | [18.7 d](/filings/0001193125-25-260124.md) | [2.6 d](/filings/0001193125-26-081475.md) | [11.0](/filings/0001193125-26-190726.md) | [1.1 d](/filings/0001193125-26-323955.md) | [11.2 d](/filings/0001193125-25-260124.md) | [13.4 d](/filings/0001193125-26-081475.md) | [7.7](/filings/0001193125-26-190726.md) | [10.8 d](/filings/0001193125-26-323955.md) |
| Capital expenditure | $m | [3.3 d](/filings/0000950170-24-122145.md) | [1.9 d](/filings/0001193125-26-081475.md) | [0.2](/filings/0000950170-25-063499.md) | [0.6 d](/filings/0000950170-25-101771.md) | [0.4 d](/filings/0001193125-25-260124.md) | [0.7 d](/filings/0001193125-26-081475.md) | [0.4](/filings/0001193125-26-190726.md) | [0.7 d](/filings/0001193125-26-323955.md) | [0.5 d](/filings/0001193125-25-260124.md) | [0.2 d](/filings/0001193125-26-081475.md) | [0.7](/filings/0001193125-26-190726.md) | [0.2 d](/filings/0001193125-26-323955.md) |
| Dividends paid | $m | [2.8 d](/filings/0000950170-24-122145.md) | [2.8 d](/filings/0001193125-26-081475.md) | [3.0](/filings/0000950170-25-063499.md) | [3.0 d](/filings/0000950170-25-101771.md) | [3.0 d](/filings/0001193125-25-260124.md) | [3.0 d](/filings/0001193125-26-081475.md) | [3.0](/filings/0001193125-26-190726.md) | [3.0 d](/filings/0001193125-26-323955.md) | [3.0 d](/filings/0001193125-25-260124.md) | [3.1 d](/filings/0001193125-26-081475.md) | [3.1](/filings/0001193125-26-190726.md) | [3.1 d](/filings/0001193125-26-323955.md) |
| Share repurchases | $m | [0.2 d](/filings/0000950170-24-122145.md) | [0.0 d](/filings/0001193125-26-081475.md) | [0.1](/filings/0000950170-25-063499.md) | [0.2 d](/filings/0000950170-25-101771.md) | [0.3 d](/filings/0001193125-25-260124.md) | [0.0 d](/filings/0001193125-26-081475.md) | [0.0](/filings/0001193125-26-190726.md) | [0.0 d](/filings/0001193125-26-323955.md) | [0.3 d](/filings/0001193125-25-260124.md) | [0.0 d](/filings/0001193125-26-081475.md) | [0.1](/filings/0001193125-26-190726.md) | [0.0 d](/filings/0001193125-26-323955.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 13,773,162 at 2026-07-24, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-323955.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.